[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641638":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":30,"responsibleParty":49,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":10,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Capital Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ischemic Stroke Cohort",null,"Patients diagnosed with ischemic stroke who undergo diagnostic lumbar puncture for clinical indications at Xuanwu Hospital, Capital Medical University. Residual cerebrospinal fluid will be analyzed by flow cytometry to assess mitochondrial content, mitochondrial membrane potential, and membrane-associated markers. Clinical outcomes will include admission NIHSS, discharge NIHSS, and 90-day modified Rankin Scale score.",[13],"Diagnostic Test: Cerebrospinal Fluid Flow Cytometry",{"label":15,"type":10,"description":16,"interventionNames":17},"Alzheimer Disease Control Cohort","Patients diagnosed with Alzheimer disease who undergo diagnostic lumbar puncture for clinical indications at Xuanwu Hospital, Capital Medical University. Residual cerebrospinal fluid will be analyzed by the same flow cytometry panel and used as a disease control group for comparison of cerebrospinal fluid mitochondrial and membrane-marker profiles.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","Cerebrospinal Fluid Flow Cytometry","Residual cerebrospinal fluid obtained during clinically indicated diagnostic lumbar puncture will be analyzed by flow cytometry. The assay will measure mitochondrial signal using MitoTracker, mitochondrial membrane potential using JC-1, and membrane-associated markers including CD45, CD41, CD24, vWF, and EAAT1. The study does not assign participants to any treatment or diagnostic procedure beyond routine clinical care.",[15,9],[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Xi Chen, MD\u002FPhD","CONTACT","8617600104266","chenxi00cx@126.com",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Xuanwu Hospital","RECRUITING","Beijing","None Selected","100053","China","CN",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},[46],{"name":47,"role":27,"phone":48,"phoneExt":10,"email":29},"Xi Chen","+86 17600104266",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":53,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Ji Xunming,MD,PhD","Principal Investigator","Xuanwu Hospital, Beijing","100641638","cerebrospinal-fluid-mitochondrial-biomarkers-in-ischemic-stroke-and-alzheimer-disease-100641638",false,"NCT07600996","Cerebrospinal Fluid Mitochondrial Biomarkers in Ischemic Stroke and Alzheimer Disease","A Prospective Observational Study of Cerebrospinal Fluid Mitochondrial Biomarkers Measured by Flow Cytometry in Patients With Ischemic Stroke and Alzheimer Disease Controls","Inclusion Criteria:\n\n* Age 18 years or older. Patients treated at Xuanwu Hospital, Capital Medical University between March 2026 and May 2026.\n\nDiagnosis of ischemic stroke or Alzheimer disease according to standard clinical diagnostic criteria.\n\nDiagnostic lumbar puncture performed for clinical indications as part of routine medical care.\n\nAvailability of residual cerebrospinal fluid after completion of clinically required testing.\n\nAbility to provide written informed consent, or availability of a legally authorized representative to provide consent when appropriate.\n\nFor ischemic stroke patients, availability of baseline neurological assessment and planned follow-up for 90-day modified Rankin Scale assessment.\n\nExclusion Criteria:\n\n* Lumbar puncture performed solely for research purposes rather than clinical indication.\n\nInsufficient residual cerebrospinal fluid volume for research flow cytometry analysis.\n\nGrossly bloody or severely contaminated cerebrospinal fluid sample that precludes reliable flow cytometry analysis.\n\nKnown central nervous system infection, malignant meningitis, or other inflammatory or neoplastic condition that, in the investigator's judgment, may substantially confound cerebrospinal fluid mitochondrial measurements.\n\nInability to obtain informed consent from the participant or legally authorized representative.\n\nMissing key clinical outcome data, including admission NIHSS, discharge NIHSS, or planned 90-day mRS follow-up for ischemic stroke participants.\n\nAny condition judged by the investigator to make the participant unsuitable for inclusion in the study.","ALL","18 Years",{"count":64,"type":65},40,"ESTIMATED","OBSERVATIONAL","This prospective observational study aims to investigate cerebrospinal fluid mitochondrial biomarkers in patients with ischemic stroke and Alzheimer disease controls who undergo diagnostic lumbar puncture for clinical indications at Xuanwu Hospital, Capital Medical University.\n\nResidual cerebrospinal fluid samples will be analyzed by flow cytometry to quantify mitochondrial content, mitochondrial membrane potential, and cellular or vesicular source-related markers. The flow cytometry panel will include MitoTracker, JC-1, and membrane-associated markers including CD45, CD41, CD24, vWF, and EAAT1.\n\nIn patients with ischemic stroke, the study will further examine whether cerebrospinal fluid mitochondrial measurements are associated with neurological severity and functional outcomes, including admission and discharge NIHSS scores and the 90-day modified Rankin Scale score. Alzheimer disease patients undergoing diagnostic lumbar puncture will serve as disease controls for biomarker comparison.",[69,70],"Ischemic Stroke","Alzheimer Disease (AD)",[72,73,74,75,76],"Cerebrospinal fluid","Mitochondria","MitoTracker","NIHSS","Stroke outcome","2026-06-14",{"date":79,"type":80},"2026-06-16","ACTUAL",{"date":82,"type":80},"2026-03-01",{"date":84,"type":65},"2026-08-30",{"name":5,"class":6},1]